Skip NavigationSkip to Content

Postmenopausal Androgen Metabolism and Endometrial Cancer Risk in the Women's Health Initiative Observational Study

  1. Author:
    Michels, Kara A [ORCID]
    Brinton, Louise A [ORCID]
    Wentzensen, Nicolas [ORCID]
    Pan, Kathy
    Chen, Chu
    Anderson, Garnet L [ORCID]
    Pfeiffer, Ruth M [ORCID]
    Xu,Xia
    Rohan, Thomas E
    Trabert, Britton [ORCID]
  2. Author Address

    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD., Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA., Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA., Cancer Research Technology Program, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Frederick, MD., Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY (TER).,
    1. Year: 2019
    2. Date: Sep
    3. Epub Date: 2019 04 25
  1. Journal: JNCI cancer spectrum
    1. 3
    2. 3
  2. Type of Article: Article
  3. Article Number: pkz029
  4. ISSN: 2515-5091
  1. Abstract:

    Background: After menopause, several androgens continue to be produced primarily by the adrenal glands; these can be converted into estrogens via aromatization or into androgen metabolites. It is unclear if androgens are associated with endometrial cancer risk independently of their being precursors to estrogens or if alternative metabolic pathways influence risk. Methods: We measured prediagnostic serum concentrations of 12 androgens and their metabolites using highly sensitive liquid chromatography-tandem mass spectrometry assays in a nested case-control study of postmenopausal women from the Women's Health Initiative Observational Study (313 endometrial cancer case subjects, 354 matched control subjects). Estrogens were previously assayed. We used conditional logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for endometrial cancer with adjustment for confounders. Results: Compared to the lowest concentrations, the highest levels of adrenal androgens were associated with increased endometrial cancer risk: dehydroepiandrosterone (5th vs 1st quintile: OR = 1.85, 95% CI = 1.06 to 3.25), androstenedione (OR = 2.36, 95% CI = 1.34 to 4.16), and testosterone (OR = 1.91, 95% CI = 1.12 to 3.24). Downstream androgenmetabolites were not associated with endometrial cancer. Although increased risks for the parent androgens were still suggested after adjustment for unconjugated estradiol, the associations attenuated, and with the exception of androstenedione, were no longer statistically significant. We also evaluated ratios of estrogens relative to their androgenic precursors; both higher unconjugated estrone:androstenedione and higher unconjugated estradiol:testosterone were associated with increased endometrial cancer risk. Conclusions: We identified increased risks for endometrial cancer with the highest levels of adrenal androgens and high levels of estrogens relative to these androgens. As adrenal androgens can be aromatized to estrogens, this suggests androgens likely influence endometrial carcinogenesis via estrogen metabolism.

    See More

External Sources

  1. DOI: 10.1093/jncics/pkz029
  2. PMID: 31321379
  3. PMCID: PMC6620792
  4. WOS: 000493383800005
  5. PII : pkz029

Library Notes

  1. Fiscal Year: FY2018-2019
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel